M ore than 7200 new cases of squamous cell carcinoma of the anus (SCCA) are diagnosed yearly in the United States. 1 However, the incidence of SCCA has been rising steadily at a rate of 2.2% per year in the last decade. Early stage cancers account for an increasing proportion of new SCCA cases, and a substantial number of these are American Joint Commission on Cancer stage I (T1N0M0). 2 Screening and early management of anal cancer and high-grade squamous intraepithelial lesions are becoming more prevalent, as evidenced by ongoing trials such as the Anal Cancer/High-Grade Squamous Intraepithelial Lesion Outcomes Research trial; this will likely increase early detection of anal cancer and thus the incidence of anal cancer diagnosed at stage I.
The standard treatment for locally advanced (stage II-III) disease is concurrent chemoradiation (CRT), which has been shown to improve disease-free survival (DFS) and colostomy-free survival (CFS) over radiotherapy (RT) alone. 3, 4 Unlike locally advanced SCCA, optimal management for early stage cancer is less clear. For anal canal and select anal margin tumors, local excision can be used if preoperative assessment suggests that adequate margins and good functional outcomes can be achieved. The benefit of CRT over radiation alone has not been well established, because patients with stage I cancer were excluded from the clinical trials demonstrating the superiority of CRT. [3] [4] [5] Several older retrospective series show excellent local control (LC) rates with RT alone. 6, 7 This is particularly true for lesions <1 cm treated with RT and a brachytherapy boost where a 9% local failure was reported. 8 More recent studies, however, suggest superior outcomes for patients with stage I or II cancer who are treated with CRT over RT alone. 9, 10 The improved LC comes at the cost of increased toxicity associated with the addition of chemotherapy to radiation. 4 Despite the lack of clear evidence, current general consensus for treatment, as evidenced by an American College of Radiology Appropriateness Criteria survey, is to treat stage I patients with CRT.
11 This is also reflected in the National Comprehensive Cancer Network guidelines. 12 Given the limited evidence, primarily from older studies, supporting these recommendations, studies of a larger number of patients treated with modern techniques are needed to understand whether CRT improves outcomes over RT alone. There is also reason for concern in using CRT over radiation alone in older (age >65 y) and sicker populations. This study uses population-based data from the Surveillance, Epidemiology and End Results (SEER) registry linked to Medicare claims to assess outcomes and compare toxicity profiles of RT versus CRT for Medicare-eligible patients (>65 y or with a disability) with stage I SCCA.
PATIENTS AND METHODS

Patient Cohort
We identified our patient cohort using data from the SEER registry merged with Medicare claims. Using relevant International Classification of Disease O3 codes (8010-8089) and anatomic site codes (C21.0M, C21.1, and C21.8), we identified 729 patients with stage I SCCA between 1996 and 2011. Patients were excluded if they were aged <55 years (n = 166) because they had high rates of disability and were less likely to have complete Medicare claims data, aged >85 years (n = 69) because of potentially poor prognosis influencing treatment decisions, and if they had received hospice care within 6 months of diagnosis. We further excluded patients who did not receive CRT or RT as first-line treatment or CRT regimens not including 5-fluorouracil (5-FU), resulting in a final cohort of 299 patients (Fig. 1) .
Study Variables
We obtained data on demographics (age, race/ethnicity, marital status, and median income in ZIP Code of residence) and clinical cancer information (tumor histology, size, and year of diagnosis) from SEER data; reason for Medicare entitlement was obtained from Medicare data. Using Medicare data, we calculated modified Charlson scores to estimate the burden of comorbid illnesses. 13 We identified patients with HIV infection using a validated algorithm.
14,15 RT was identified using SEER and Medicare claims. Chemotherapy was determined from Medicare data within a 90-day period after cancer diagnosis.
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Outcomes
The primary outcome was overall survival (OS), determined from vital status information provided by Medicare through December 31, 2013; all of the patients were censored by that date. We also assessed cancer-specific survival (CSS) using cause of death and survival time data from SEER. Other study outcomes included CFS, determined by identifying International Classification of Disease, Ninth Edition, and Current Procedural Terminology codes, and treatment for SCCA recurrence or progression. We identified recurrence or persistence of SCCA by finding subsequent episodes of SCCA registered in SEER, as well as Medicare claims signifying treatment for invasive SCCA with RT, chemotherapy, salvage surgery, or colostomy, >6 months after the initial cancer episode. We classified cases with anal cancer as the cause of death or hospice care with a primary diagnosis of anal cancer as persistent or recurrent SCCA to capture patients who did not receive treatment. DFS was defined as an absence of disease recurrence of persistence as defined above.
We then ascertained and categorized adverse events potentially related to SCCA treatment, occurring within 6 months of treatment initiation, using relevant diagnos-tic codes. These events are classified as early toxicity. We repeated the same analysis for >6 months, referred to as late toxicity. Early and late toxicities included ulcer, abscess, bleeding, cystitis, dermatitis, erectile dysfunction, fissure, fistula, incontinence, pain, proctitis, stricture, and hematuria. Chemotherapy-associated toxicities were independently assessed and included bacterial infection, blood transfusion, cellulitis, dehydration, electrolyte abnormality, emesis, fever, neutropenia, pulmonary embolism, platelet transfusion, pneumonia, sepsis, thrombocytopenia, and urinary tract infection.
Statistical Analysis
We compared baseline characteristics of patients with SCCA by treatment group (lone RT versus CRT), using a t test for normally distributed continuous variables and χ 2 test for categorical variables. OS, anal CSS, CFS, and DFS were compared in those who received CRT versus lone RT using Kaplan-Meier methods. This study was deemed exempt by the institutional review board of the Icahn School of Medicine at Mount Sinai.
To account for factors possibly confounding the relationship between treatment group and outcomes, we used propensity-score methods. Propensity scores (PSs) represent the probability that a subject would be assigned to CRT treatment (versus lone RT) based on baseline characteristics and were generated using a logistic regression model including sociodemographic characteristics, tumor characteristics, comorbidity score, HIV status, use of home health services (as a proxy for functional status), and cytologic screening before cancer diagnosis as predictors. After matching, we tested for differences in baseline cohort characteristics to ensure balance in the 2 treatment groups.
To compare effectiveness of CRT versus RT, we fitted unadjusted Cox regression models with OS, CSS, CFS, and DFS as outcomes. We then fitted similar models adjusting for PSs for CRT use. We then matched patients treated with and without CRT by their PS. 17 We then used logistic regression to calculate odds of adverse events in patients treated with CRT compared with lone RT. On the basis of the number of deaths observed among patients in the cohort, we estimated that the primary adjusted analysis had an 80% power to detect a hazard of death associated with CRT compared with lone RT of ≈0.75 at a 0.05 significance level. Analyses were performed in SAS 9.3 (SAS, Cary, NC).
RESULTS
The analytic sample had a median age of 72 y, with a large proportion of white women. These demographic factors did not differ by treatment group (Table 1 ; all p > 0.06). Median follow-up for patients receiving RT and CRT was 43 (95% CI, 25-71 mo) and 73 months (95% CI, 43-122 mo). Patients receiving RT alone tended to be older with a higher prevalence of end stage renal disease, although neither achieved statistical significance. A higher percentage of patients were treated with RT alone versus CRT from 2008 to 2011 compared with earlier years (p = 0.01), but there was no significant difference in the use of intensitymodulated radiation therapy (IMRT). In addition to 5-FU, 150 CRT patients (75%) were treated with mitomycin-C, 18 (9%) were treated with platinum-based agents, and the remaining patients received lone 5-FU.
Unadjusted analyses showed that there was inferior OS at 5 years for patients receiving RT alone (61% (95% CI, 49%-70%)) compared with CRT (73% (95% CI, 66%-79%); p = 0.002). However, there was no difference in other oncologic parameters (Fig. 2) . Specifically, 5-year CSS was 84% (95% CI, 72%-92%) for RT versus 90% (95% CI, 85%-94%; p = 0.1) for CRT. Likewise, the rate of patients spared an APR at 5 years was 92% (95% CI, 84%-96%) for RT versus 87% (95% CI, 81%-91%; p = 0.6) for CRT. There was also no difference in DFS at 5 years, with 82% (95% CI, 73%-89%) for RT versus 82% (95% CI, 75%-86%) for CRT (p = 0.9). For patients with evidence of disease recurrence, 16 (29%) had surgical resection >90 days postdiagnosis, 16 (29%) had an abdominoperineal resection, 31 (56%) had a subsequent colostomy, and 13 (24%) went to hospice with a primary diagnosis of SCCA.
To address potential confounding in treatment assignment, adjusted and PS matching was performed. After applying PS methods, there was no significant difference in OS (PS-adjusted p = 0.05; PS-matched p = 0.08) and continued to be no difference in CSS, CFS, or DFS between RT and CRT (Table 2) .
Differences in early and late toxicities were compared between the 2 groups, and significantly different toxicities are shown in Table 3 . With regard to short-term toxicities, CRT was associated with higher frequency of pain (OR = 2.5 (95% CI 1.1-5.9)) and proctitis (OR = 2.9 (95% CI, 1.5-5.6)) in both unmatched and 1:1 PS-matched cohorts (data not shown). Among those in the CRT treatment group, the frequency of the chemotherapy-associated toxicities dehydration, electrolyte abnormality, emesis, and neutropenia exceeded 20%. There remained statistically significant differences in late toxicities including bleeding (OR = 2.0 (95% CI, 1.2-3.4)) and proctitis (OR = 2.1 (95% CI, 1.2-3.5)), which was again seen in both unmatched and matched cohorts (data not shown). There were no significant differences in other late toxicities, including pain, stricture, fistula, incontinence, ulcer, and erectile dysfunction.
DISCUSSION
In our population-based cohort of older patients with stage I SCCA, there was no statistically significant benefit in CSS, CFS, or DFS for CRT compared with those who received RT alone and no significant difference in OS after adjustment for confounding. Furthermore, the frequency of chemotherapy-associated toxicities was high, and the odds of RT-associated toxicities, both early and late, was higher among those who received CRT versus lone RT. This study is the largest comparative analysis evaluating the outcomes of patients with stage I cancer who were treated with RT alone versus CRT. It also reflects a more modern treatment era with improved imaging for staging, better radiation techniques, and better supportive chemotherapy delivery. The superior OS among those who re- ceived CRT in unadjusted analyses is likely an artifact of the selection bias of only giving chemotherapy to better performing patients and was eliminated after applying PS methods to balance the treatment groups. It is difficult to believe that chemotherapy improves OS in the absence of improving DFS or CFS and in the context of the randomized trials for advanced-stage disease not showing an OS benefit for CRT over RT alone.
3,4
The addition of chemotherapy to radiation in anal cancer serves to improve LC only and does not appear to affect the risk for developing metastatic disease. This is best characterized in the long-term follow-up of the Anal Cancer Trial (ACT) I, where there was a statistically significant 25.3% reduction in locoregional relapse at 12 years but no significant increase in the rates of combined locoregional relapse/distant relapse or distant relapse alone. 18 The data presented here confirm that not only is there no difference in CFS (presumably the best reflection of salvageable local failure), but there was no difference in DFS or CSS as well.
The DFS rates in the present cohort more closely approximate the 5-year DFS of stage II to III versus that which would be expected of stage I SCCA. Most likely, this stems from our definition of local recurrence from SEER and Medicare claims, which likely overestimates the true recurrence rate. The definition that we used for DFS is as conservative as possible to avoid adding bias to the analysis. This fact is reflected in the relative low colostomy rates: if local failures were really so high, presumably there would be a commensurately higher salvage colostomy rate. It is possible that the low DFS rate in this series is because it is an older population with worse OS and because of possible misclassification of cause of death as secondary to anal cancer, which is one of the criteria used to classify a case as not disease free. However, our classification scheme was similarly applied to both treatment arms and should not systematically bias our analyses comparing outcomes of patients treated with CRT versus lone RT.
Although CRT has been shown in multiple randomized trials to improve outcomes for stage II to III SCCA, this added benefit has never been shown in stage I. Much of the evidence supporting the use of CRT in this population comes from older retrospective series, spanning decades of accrual and a variety of treatment techniques. In most of these older series, patients with stage I and II are lumped together, making it difficult to discern outcomes in true stage I patients. We have carefully attempted to dissect out outcomes of the true T1N0 population. One of the largest series consists of 69 tumors <1 cm treated with RT and had a 91% LC rate at 50 months and 89% 5-year DFS. 8 Another series of 26 T1 tumors showed 81% LC treated with RT, with or without brachytherapy. 7 A smaller American series with 6 T1 tumors found no advantage to CRT versus RT. 6 Two more modern series have attempted to compare CRT versus lone RT in T1 and T2, suggesting improved outcomes with CRT. 9, 10 However, a closer look shows that numbers of T1 patients are very small (24 and 29), and the benefit of CRT was possibly limited to T2 disease.
Despite the paucity of evidence, it appears that many consensus groups favor CRT over RT alone for stage I SCCA. The American College of Radiology Appropriateness Criteria recommend CRT for a 73-year-old patient with Karnofsky performance status 80 with the highest possible score of usually appropriate and RT alone with the lowest possible score to be considered may be appropriate.
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National Comprehensive Cancer Network recommends radiation with or without concurrent chemotherapy for T1N0 anal margin tumors but states that "concurrent CRT is the recommended primary treatment for patients with nonmetastatic anal canal cancer. 12 " The sources cited for these recommendations come from the same small series where T1 lesions were obscured by the benefit probably coming from T2. The data presented here showed a significant trend favoring radiation alone over CRT in more recent years. The reason might reflect more comfort with radiation dose escalation instead of chemotherapy in the IMRT era. SEER-Medicare does not record radiation dose, so this hypothesis cannot be tested. Arguing against this is that there was no significant difference in IMRT usage between the cohorts. In addition to not improving oncologic outcomes for T1N0 lesions, the results of this study show that adding chemotherapy to radiation comes at the cost of higher toxicity. A course of definitive radiation to the anus is a very difficult treatment to tolerate, with grade 3 skin desquamation, diarrhea, pain, and dysuria being almost standard. These effects are noticeably amplified in the clinic with the addition of chemotherapy, especially when patients receive the second of 2 doses of 5-FU and mitomycin-C at week 5, dramatically amplifying the skin reaction. What is perhaps more concerning from this analysis is that late toxicities, namely bleeding and proctitis, persist at a 2-fold higher rate in the CRT group. In contrast, the13-year update of ACT I did not show any differences in late toxicity; however, the ACT I data do not look at specific toxicities like the data presented here and might have missed events like late proctitis and bleeding. 18 A significant limitation of this study is applying these results to all patients with anal cancer. These patients are older and include more women, and with higher comorbidities than one might see in a typical practice. Only 6% are HIV infected. As such, these results should be viewed with caution when extrapolating to a young, healthy patient who potentially has more time to manifest recurrence. In addition, we were unable to determine whether lesions were anal margin or anal canal. The surrogate used for persistent or recurrent disease also appears to produce numbers higher than historical controls. It is possible that clinicians billed follow-ups under a diagnosis of anal cancer, which, according to our definition, would be scored as persistent or recurrent disease. Also, there is no information as to radiation dose and technique. As in any retrospective series, there is significant clinician bias, and, even with propensity matching, we were not able to completely eliminate it. This is most evidenced by the decreased OS in the RT-alone arm in the unmatched cohorts. Although established criteria were used for the comorbidity score, there is clearly a limitation because some competing factor(s) is not being accounted for, despite our best statistical attempts to remove it. We hypothesize 2 possible reasons: first, the comorbidity score does not quantitate severity of comorbidities, just presence or absence. Second, there is a patient gestalt that only a clinician in front of a patient can estimate; 2 patients, with identical comorbidities on paper can be very different candidates for treatments. Despite our best attempts to uncover this bias, we were not able to fully do so.
CONCLUSION
In the absence of a prospective trial, SEER-Medicare is probably the best data set available to explore outcomes in a relatively rare disease with limited patient numbers. A prospective clinical trial is the best way to definitely answer this question, but it is hard to imagine such a trial being run given the cost and numbers required for a noninferiority design. At the very least, this study suggests that clinicians should take pause before committing older and sicker patients with stage I SCCA to CRT over RT alone.
